Improvements in pacemaker energy consumption and functional capability: four decades of progress.
Explore the source record for details and available documents.
Algorithms↗
Biomedical subjects
O J Ohm
Publications and source records attributed to O J Ohm.
Clinical performance of steroid-eluting pacing leads with 1.2-mm2 electrodes.
To raise pacing impedance and reduce battery current drain, new tined steroid-eluting leads were developed with 1.2-mm2 hemispherical electrodes, instead of conventional 5-8 mm2. Twenty-two unipolar J-shaped atrial leads and 25 unipolar ventricular leads (models 4533 and 4033, respectively) were implanted in 33 consecutive patients and followed for a mean of 25 months (range 18-29). Handling characteristics of atrial leads were found favorable. The leads slipped easily into the right atrial appendage and were easy to position. Handling characteristics of ventricular leads were satisfying, but more efforts had to be applied to cross the tricuspid valve. Special care was taken to avoid perforation of the myocardium due to the small lead tip. Following implantation, four ventricular and one atrial lead exhibited instability of pacing thresholds that resolved spontaneously within 1-3 days of implantation. Except for this, no lead malfunctioned. The reoperation rate was zero. The mean electrogram amplitudes of 15 mV (ventricle) and 4 mV (atrium), and the mean chronic pacing threshold of 0.085 ms at 1.6 V (app. 0.43 V at 0.5 ms) were comparable with the best values seen in the literature on passive fixation leads. The rest of the electrophysiological parameters were enhanced: mean pacing impedances were 984 omega (acute) and 900 Q (chronic), mean slew rates 3.26 V/s (ventricle) and 1.75 V/s (atrium), mean acute voltage threshold at 0.5 ms was 0.25 V, mean current and energy thresholds calculated at 0.5 ms were 260 microA and 32 nJ (acute) and 478 microA and 103 nJ (chronic). The electrical characteristics of these leads provide for increased pacemaker longevity in combination with substantial safety margins for pacing and sensing.
Arrhythmias, Cardiac↗
[New therapeutic methods for tachycardia].
Explore the source record for details and available documents.
Catheter Ablation↗
New temporary atrial and ventricular pacing leads for patients after cardiac operations.
We have studied two new temporary pacing leads (Medtronic 6491 and 6492) intended for pacing after cardiac operations. The conductor has stainless steel strands coated with polyethylene connected to a 4' mm2 surface area, stainless steel, smooth, tapered electrode. A soft 4-0 coiled polypropylene fiber served as as fixation mechanism in the heart. The study included 15 children (aged 3 months to 7 years, body weight 4.4 to 20 kg) with a variety of congenital heart defects and 15 adults (aged 45 to 78 years) with coronary artery disease (n = 13) and aortic valve disease (n = 2). A pair of leads each was placed in a bipolar fashion in the right atrial wall and nonsystemic ventricle in the children (median implant duration 12 days) and in the right atrial wall only in the adults (median implant duration 9 days). The atrial current threshold values in children increased from 0.61 +/- 0.34 mA immediately after implant to 2.08 +/- 1.86 mA at explant (p < 0.002). In the adults the threshold values increased from 0.95 +/- 1.44 mA immediately after implant to 2.76 +/- 2.76 mA at explant (p < 0.002). In the ventricle the threshold values increased from 0.38 +/- 0.13 mA immediately after implant to 2.22 +/- 1.63 mA at explant (p < 0.002). Tissue resistance immediately after implant measured 809 +/- 182 omega at explant (children, p = not significant). Corresponding values in adults were 778 +/- 190 omega and 599 +/- 91 omega (p < 0.004). In the ventricle resistances changed from 1019 +/- 143 omega to 876 +/- 137 omega (p < 0.05). P wave amplitudes measured 1.8 +/- 1.5 mV immediately after implant and decreased to 1.6 +/- 1.2 mV at explant (p = not significant, children) and 2.0 +/- 1.3 mV to 1.8 mV (p = not significant, adults). R wave amplitude were 13.1 +/- 3.0 mV immediately after implant and fell to 8.7 +/- 4.5 mV at explant (p < 0.005). Thus, threshold values, tissue resistances, and electrogram and pliable amplitudes assured a safe pacemaker function. The small diameter and pliable texture of these leads provided a smooth surgical handling. They were found particularly suitable in children.
Aged↗
Preliminary experience with nonthoracotomy implantable cardioverter defibrillators in young patients. The Medtronic Transvene Investigators.
Implantable cardioverter defibrillators represent an important treatment option for patients with life-threatening tachyarrhythmias. However, the requirement for surgical access to the thorax contributes to significant procedural morbidity with ICD implantation. This study was performed to assess an initial experience with a nonthoracotomy approach to ICD lead implantation in young patients. An international survey identified 17 patients, ranging in age from 12-20 years (mean = 16.7 +/- 2.4) and weighing from 33-89 kg (mean = 60.6 +/- 13.3), who had undergone placement of the Medtronic Transvene defibrillator lead system. Implant indications were aborted sudden cardiac death in 15 patients and recurrent ventricular tachycardia or familial sudden death in 2 patients. At a median follow-up of 7.9 months, 9 of 17 patients had received at least one ICD therapy. There have been no deaths. Complications included patch or generator erosion (3 patients), lead dislodgement (1 patient), and ICD system infection requiring explanation (1 patient). The initial experience with nonthoracotomy ICDs in young patients appears promising. This approach may be particularly advantageous for patients who have undergone prior thoracotomy. Prospective clinical trials will be required to establish the applicability of these lead systems to select patient populations.
Adolescent↗
Long-term clinical performance of a central venous oxygen saturation sensor for rate adaptive cardiac pacing.
Rate adaptive ventricular pacemakers using central venous oxygen saturation (O2Sat) to control the pacing rate have been implanted in 14 patients (mean age 71 years), with a mean follow-up period of 44 months (range 2-63 months). In eight patients the pacemakers were replaced due to signs of battery depletion after an implant duration of 39-58 months. During bicycle exercise testing the O2Sat decreased on average from 61% +/- 4% at rest to 36% +/- 4% (P < 0.0001) at peak exercise, and the maximum pacing rate was 122 +/- 5 beats/min. The time delay until the O2Sat had dropped 10%, 65%, and 90% of the total reduction during exercise was 4.8 +/- 0.9 seconds, 39.8 +/- 3.8 seconds, and 71.3 +/- 7.5 seconds, respectively. The O2Sat decreased 9.4% +/- 2% (P < 0.005) from resting supine to resting sitting. Oxygen breathing increased the telemetered O2Sat from the pacemaker by 8.4% +/- 1% (P < 0.001). During follow-up the O2Sats were relatively stable in 50% of the patients, but demonstrated significant fluctuations in the others. At 1-year invasive follow-up O2Sat measured by the pacemaker decreased 22% +/- 2%, and in blood samples from the right ventricle 22% +/- 2% from rest to 3 minutes exercise at 25 watts. There was a significant correlation between O2Sat measured by the pacemaker and in blood samples from right ventricle (n = 105; r = 0.73; P < 0.001). In two patients the O2Sat dropped significantly during pneumonia. In another patient episodes of angina pectoris was associated with low O2Sat and a concomitant fast pacing rate.
Aged↗
Clinical study of a new activity sensor for rate adaptive pacing controlled by electrical signals generated by the kinetic energy of a moving magnetic ball.
A new rate adaptive pacemaker (Sensorithm) controlled by an activity sensor providing electrical signals induced by a magnetic ball moving freely in an elliptical cavity surrounded by two copper coils, was implanted in ten patients; mean age of 75 years (range 64-89). Six patients had atrioventricular block and four had sinus node disease. In auto-set testing procedure during a 1-minute walk in the corridor, a slope resulting in a maximum rate of 95 beats/min was selected in every patient, and a medium reaction time was programmed. During graded treadmill exercise tests the heart rate increased 63 +/- 7 beats/min to 135 +/- 6 beats/min in rate adaptive pacing mode (VVIR), and 15 +/- 6 beats/min (P < 0.0001) in ventricular pacing mode (VVI). The symptom-limited exercise time was 9.1 +/- 1.1 minutes and 8.2 +/- 1.2 minutes (P = NS), and the exercise distance was 501 +/- 95 meters and 428 +/- 92 meters (P < 0.05) in VVIR and VVI pacing mode, respectively. The maximum oxygen uptake was 20.6 +/- 2.6 mL/kg per minute in VVIR pacing and 18.1 +/- 2.1 mL/kg per minute (P < 0.05) in VVI pacing. The delay time until the pacing rate increased 10% of the total rate increase at onset of treadmill exercise was 4.4 +/- 0.7 seconds.(ABSTRACT TRUNCATED AT 250 WORDS)
Aged↗
The acute effects of induced tachycardia on coronary sinus and arterial plasma levels of atrial natriuretic peptide and on arterial catecholamines.
Atrial natriuretic peptide (ANP) was measured in coronary sinus (CS) plasma in seven patients with induced tachycardia. Right atrial pressure (RAP) and femoral artery (FA) levels of ANP, noradrenaline (NA) and adrenaline (A) were measured before and after 5 min with tachycardia. During tachycardia, ANP in CS plasma increased from 381 +/- 273 (mean +/- SD) to 1376 +/- 1191 pmol l-1 (p < 0.0001), and ANP levels in FA plasma from 89 +/- 48 to 231 +/- 151 pmol l-1 (p < 0.005). A significant increase was observed for peak RAP, whereas mean RAP remained unaltered. While no correlation existed between the increase in CS plasma ANP level and RAP, significant correlations were found between the changes in FA plasma ANP and RAP, and between FA plasma levels of ANP and NA. Following tachycardia, significant correlations were found both between ANP in CS and FA plasma and between the changes in these plasma levels. Whereas the changes in FA plasma levels of ANP during tachycardia seems dependent of RAP and arterial plasma levels of NA, the CS plasma ANP level appears to be independent of the two factors, probably because CS plasma ANP are drained mainly from the left side of the heart.
Adult↗
[Treatment of ventricular tachyarrhythmias with an implantable pacemaker-cardioverter-defibrillator].
During the period from November 1989 to January 1992, 17 patients with ventricular tachyarrhythmias received an implantable pacemaker-cardioverter-defibrillator. The material consists of three female and 14 male patients with an age range of 13-66 years, mean 50.8 +/- 16.6 years. 13 patients had coronary artery disease, one cardiomyopathy, one a myocarditis sequela and two primary rhythm disorder. Four patients received epicardial and 13 endocardial electrode systems. The observation period varied from 4-30 months (april 1992), mean 15.2 +/- 8.8 months. 11 out of 17 patients (65%) experienced one or more episodes of tachyarrhythmias which was treated successfully with overdrive pacing (ramp or burst), cardioversion or defibrillation. One patient died of heart failure after an observation period of 13 months. His pacemaker-cardioverter-defibrillator had been activated more than 100 times. Two children, 13 and 15 years, were treated successfully for ventricular fibrillation four and five months after implantation of the device. The actual one year survival is 100%. Assuming that therapy with a device had not taken place, and that the six patients who experienced episodes of ventricular fibrillation died, the hypothetical probability of survival would have been 62.1 +/- 12.3%.
Adolescent↗
[Sudden cardiac death].
Sudden cardiac death is instant unexpected death that occurs within one hour of an abrupt change in a person's stable clinical state. The mechanism is generally a ventricular tachyarrhythmia. The underlying pathology is usually coronary heart disease. In 1990, 18 patients who survived sudden cardiac death, excluding those with acute myocardial infarction, were evaluated and treated in our institution. 15 patients had coronary heart disease, one had hypertrophic cardiomyopathy, one had dilated cardiomyopathy and one had a replaced aortic valve. Evaluation included heart catheterization and electrophysiological examination. Treatment was specifically tailored to each patient according to etiology, results of all tests and the patient's prognostic factors. Treatment included a permanent pacemaker-cardioverter-defibrillator, antiarrhythmic drug therapy, aortocoronary bypass and betablocker therapy.
Aged↗
[Intermittent bradyarrhythmia in infants and small children treated with permanent pacemaker].
Four children aged two, two and four months and five years respectively, with intermittent cardiac bradyarrhythmias and otherwise normal hearts are described. The diagnoses were based upon findings by telemetry and 24-hour ECG-recordings. Two patients had sinus node disease, one patient had intermittent complete atrioventricular block, and the fourth had a permanent first degree atrioventricular block and intermittent high grade second degree atrioventricular block. All patients presented serious symptoms with apparent life-threatening events before admission. They were given a permanent cardiac pacemaker. One patient experienced recurrent excessive increase in the myocardial stimulation threshold, leading to further syncopal episodes. All patients are developing adequately with normally functioning pacemakers.
Bradycardia↗
Ocular deformation after long-term repeated bulbar compression for termination of paroxysmal tachycardia.
Explore the source record for details and available documents.
Eye Injuries↗
Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter-defibrillator. Results of a European multicenter study of 102 implants.
BACKGROUND: Third-generation implantable cardioverter-defibrillators are devices designed to treat ventricular tachycardia (VT) and ventricular fibrillation (VF) by means of overdrive pacing, cardioversion, or defibrillation. So far, the efficacy of tiered therapy has been documented only in small series. Therefore, a European multicenter clinical evaluation study of a new tachyarrhythmia control device, the Medtronic PCD pacer-cardioverter-defibrillator with epicardial patch-lead configuration, was undertaken. METHODS AND RESULTS: We report on 102 patients (mean age, 55 +/- 13 years) from 11 European centers. PCD devices implanted between May 1989 and February 1991 were included. The patients suffered from hemodynamically significant ventricular tachyarrhythmias not suppressed by antiarrhythmic drug therapy and unrelated to acute myocardial infarction; one patient had nonsustained VT and severely depressed left ventricular function. Seventy patients had coronary artery disease with old myocardial infarctions, 23 had cardiomyopathies of various etiologies, and nine patients had no detectable heart disease. Mean ejection fraction was 36 +/- 14% (range, 10-76%). Mean intraoperative defibrillation threshold (51 patients) was 10.6 +/- 5.1 J (range, 2-18 J). The documented follow-up ranged from 1 to 21 months (mean, 9.4 +/- 5.8 months), or 79.9 cumulative patient-years. Perioperative mortality was 3.9%. The actuarial survival rate at 12 months was 91%. One sudden arrhythmic death occurred. Sixty patients (58%) received device therapy. Seventeen patients had therapies only for "VF" episodes, 16 patients only for VT, and 28 patients for VT and "VF" episodes. Based on device memory data, 1,235 spontaneous VT episodes were detected and treated in 43 patients. Twelve hundred four of these VT episodes received painless initial antitachycardia pacing therapy, restoring sinus rhythm in 91%. The 108 ongoing episodes received 209 multiple therapeutic attempts. Eighty-five additional overdrive pacing therapies restored sinus rhythm in 30%. Initial ineffective antitachycardia pacing therapies received 51 cardioversion pulses. The success rate was 61%. Seventy-three additional cardioversion pulses were delivered to backup ineffective pacing therapy as well as ineffective secondary cardioversion pulses. Their success rate was only 40%. Two hundred eighty-six spontaneous episodes were detected in 44 patients as "VF." Overall defibrillation efficacy was 97.6%. CONCLUSIONS: The implanted device nearly eliminates sudden arrhythmic death in patients with documented, potentially fatal ventricular tachyarrhythmias. Automatic tiered therapy is highly effective to restore sinus rhythm, provided that an integrated two-zone tachycardia detection algorithm is used, assigning lower tachycardia rates to overdrive pacing and/or cardioversion and higher tachycardia rates to defibrillation. In general, spontaneous VTs can be terminated by automatic overdrive pacing, and painful or disturbing countershock therapies are not required to terminate the majority of spontaneous VT episodes.
Death, Sudden, Cardiac↗
The influence of supine relaxation on blood pressure, heart rate and atrial natriuretic peptide in normal subjects.
The effect of recumbent rest on plasma atrial natriuretic peptide (ANP) concentration, mean blood pressure (MBP) and heart rate was studied in 26 normal human volunteers. Plasma ANP concentration, MBP and heart rate were determined after 10 min sitting and after 2, 5, 8, 15 and 30 min of recumbency. During the first 5 min of recumbency there were significant decreases in both MBP (p less than 0.001) and heart rate (p less than 0.001) compared with sitting. There was a small but significant fall in plasma ANP concentration (p = 0.02) after 30 min of recumbency compared with sitting. No further reduction in MBP or heart rate occurred after 5 min supine. The level of MBP following 5 min supine correlated significantly (r = 0.44; p = 0.02) with the plasma ANP concentration 25 min later. Blood pressure and heart rate are highly dependent on posture and relaxation, and plasma ANP concentration in lesser degree. It is necessary to wait for stable baseline values to develop before any comparisons between blood pressure and plasma ANP are done. If it is assumed that a causative relation exists between blood pressure and plasma ANP level, it appears there may be a delay of 20-30 min between a change in blood pressure and the physiological response of plasma ANP level. This observation may have implications for the interpretation of the relation between blood pressure and plasma ANP concentration in healthy individuals.
Adult↗
Electrophysiologic and clinical effects of flecainide for recurrent paroxysmal supraventricular tachycardia.
The antiarrhythmic effects of flecainide acetate were evaluated in 9 patients with paroxysmal atrioventricular (AV) nodal tachycardia and 17 patients with AV tachycardia. An electrophysiologic study was performed before and after intravenous flecainide acetate, 2 mg/kg body weight, was infused over 15 minutes and was followed by a maintenance infusion of 1.6 mg/kg given over 1 hour to 26 patients and during oral treatment to 15. Treatment with oral flecainide acetate was continued for 14 +/- 5 months. Intravenous flecainide acetate terminated AV nodal tachycardia by blocking the retrograde fast pathway conduction in 7 of 7 patients and AV tachycardia by blocking retrograde conduction in the extranodal pathway in 10 of 10 patients. AV nodal tachycardia and AV tachycardia were noninducible in 8 of 9 patients (90%, p less than 0.001) and 11 of 17 patients (65%, p less than 0.001), respectively. Long-term treatment with oral flecainide acetate suppressed AV nodal tachycardia and AV tachycardia in 8 of 9 patients (90%, p less than 0.001) and 11 of 17 patients (65%, p less than 0.001), respectively. A favorable outcome was associated with block in the accessory pathway after intravenous flecainide acetate and noninducibility during oral treatment. Recurrences preferentially occurred in the younger patients. Flecainide acetate is effective in the acute and long-term management of paroxysmal supraventricular reentry tachycardia by suppressing conduction through the retrograde fast limb of the tachycardia circuit. The clinical effect can be predicted by electrophysiologic testing.
Adolescent↗
Sudden death caused by heart block in a patient with multiple myeloma and cardiac amyloidosis.
A patient with multiple myeloma and amyloidosis was admitted to hospital following successful cardiopulmonary resuscitation at home. No disturbances in heart rhythm were seen during the first 48 hours of continuous telemetric ECG recording. The patient died from ventricular asystole due to complete atrioventricular block, while he was on a 24-hour Holter monitoring the fifth night in hospital. Patients with known cardiac amyloidosis and syncope should undergo long-term ECG recordings, preferably by telemetry. Repeated registrations may be necessary to discover disturbances in heart rhythm.
Amyloidosis↗
Combined intoxication with digitoxin and verapamil. The possible inhibition of sensitisation to digitalis-specific antiserum by toxic drug concentrations.
The clinical course in a patient with a combined intoxication with digitoxin (maximal serum level 357 nmol/l) and verapamil is described. The patient received two injections of digitalis-specific antiserum. No adverse reactions to the therapy was seen, and the antiserum markedly shortened the plasma half-life of digitoxin. In vitro studies indicate that digitoxin in concentrations seen during the intoxication may have an immunosuppressive effect, thereby reducing the risk of sensitisation to the antiserum.
Aged↗
A time-related study by Doppler and M-mode echocardiography of hemodynamics, heart size, and AV valvular function during activity-sensing rate-responsive ventricular pacing.
Noninvasive Doppler and M-mode echocardiography were used to: measure stroke volume (SV), left atrial (LA) size, left ventricular end-diastolic (EDD), end-systolic dimensions (ESD), left ventricular fractional shortening (FS), and for determination of mitral and tricuspid insufficiency (MI and TI) before starting and after 1, 3, and 6 months of rate-responsive ventricular pacing (RRP). The study group consisted of 13 patients (mean age, 75 years) who could be expected to benefit from an increase in cardiac output mediated by an increment of heart rate during exercise. In VVI + activity mode (RRP), the pacemaker was programmed to a basic heart rate of 60 and a maximum heart rate of 125 bpm. The SV at rest was 71 +/- 5 before RRP, and fell to 57 +/- 4 after 3 months (p less than 0.05) and to 53 +/- 4 ml/beat after 6 months of RRP (p less than .01). The LA size and ESD were unchanged during follow-up. The EDD decreased from 6.2 +/- 0.3 to 5.4 +/- 0.2 (p less than 0.002) during the first 6 months of RRP. The FS was reduced from 33 +/- 4 to 27 +/- 3% (p less than 0.02) during the first 6 months of RRP. Four of 6 patients treated previously with a VVI pacemaker (mean duration, 9 years) had MI + TI, and 3 of the 7 patients not paced previously had MI before RRP. In the last group, 1 new patient developed MI, 1 new patient developed MI + TI, and 2 patients who had MI also developed TI within 6 months of pacing. Thus, of 13 patients, 9 (69%) had either MI or MI + TI.
Aged↗